Resilience of Pharma Supply Chains and the Impact of Covid-19 Pandemic
The addition of Archemin BV strengthens PharmaLex’s existing expertise supporting the life science industry
Frankfurt, Germany – March 11, 2021: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has completed the merger of Archemin BV to the PharmaLex Group
Established in 1999, Archemin is a well-established pharmaceutical consultancy based in Mechelen, Belgium. Headed by its founder Ludwig Everaert, and supported by Anne Peeters, Operations Manager, their multidisciplinary team of 16+ experts provide services to both domestic and international clients.
The merger complements our existing services by adding pharmacovigilance, quality management, medical information and market access consulting, allowing us to both increase our pool of expertise as well as our presence in the region. To build on our regional setting, Archemin will be a pivotal member of our France BENELUX region.
“We are really excited to be part of the PharmaLex Group”, explained Ludwig Evereart, Founder Archemin BV. “It not only allows us to continue to provide our excellent service to clients but also to be able to offer them a wider range of services with expertise across the globe”, he added. “We have worked with the team at Archemin on a number of key projects in the past”, explained Sophie Guillaume, Regional Managing Director, France and BENELUX. “Their expertise, particularly in market access, local regulatory as well as ad promo requirements and pharmacovigilance, is exemplary”, she added.
“Archemin have a strong presence in the BENELUX region and this is an important location for PharmaLex.”, explained Dr. Thomas Dobmeyer, CEO PharmaLex. “Strengthening our existing expertise in this region means we now have offices in all key areas in Europe”, he concluded.
-Ends-
About PharmaLex <Confidence beyond compliance>:
PharmaLex is a leading provider of specialised services for the pharma, biotech and medical device industries. We guide you from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technology-enabled solutions to support you through the entire product lifecycle. We deliver exceptional results — going above and beyond the standard to deliver tailor-made solutions worldwide.
The PharmaLex Group now has over 1300 employees, with 39 offices in 22 countries and more than 600 satisfied clients worldwide.
For further information, please contact:
Ms. Eva Keck
PharmaLex GmbH; Director, Business Development Operations
eva.keck@pharmalex.com
+49 621 18 15 38 0
Harrlachweg 6
68163 Mannheim
Germany
Related posts
